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Abstract  
Glycolipid antigens recognized by  T cell receptors (TCRs) drive the activation of invariant natural killer T  
(iNKT) cells, a specialized subset of innate T lymphocytes.  Glycolipids with -linked anomeric carbohydrates 
have been identified as potent microbial lipid antigens for iNKT cells, and their unusual -anomeric linkage has 
been thought to define a ‘foreign’ lipid antigen motif.  Yet mammals use endogenous lipids to select iNKT cells, 
and there is compelling evidence for iNKT cell responses in various types of sterile inflammation.  The nature 
of endogenous or environmental lipid antigens encountered by iNKT cells is not well defined.  Here, we sought 
to identify lipid antigens in cow’s milk, a prominent part of the human diet.  We developed a method to directly 
capture lipid antigens within CD1d-lipid-TCR complexes, while excluding CD1d-bound to non-antigenic lipids, 
followed by direct biochemical analysis of the lipid antigens trapped at the TCR-CD1d interface.  The specific 
antigens captured by this ‘TCR trap’ method were identified as -linked monohexosylceramides by mass 
spectrometry fragmentation patterns that distinguished - from -anomeric monohexosylceramides.  These 
data provide direct biochemical evidence for -linked lipid antigens from a common dietary source.  
 
Significance Statement 
Invariant natural killer T (iNKT) cells are activated quickly and play a key role in the control of many microbial 
infections via their ability to rapidly secrete cytokines and chemokines that enhance many immune responses.  
Microbial glycolipid antigens that activate iNKT cells have been identified as -anomerically linked glycolipids.  
However, the nature of the endogenous lipid antigens that are important contributors to the biology of iNKT 
cells has been unclear.  In this study, antigenic lipids from cow’s milk were isolated using a T cell receptor trap 
method, and their stereochemical structures were determined to be hexosylceramides with -linked hexose 
headgroups, thus identifying dietary lipid antigens for iNKT cells.     
 
\body 
Introduction 
Adaptive mammalian T lymphocytes are well known for their use of combinatorial diversity to generate a broad 
repertoire of antigen receptors, a process that evolved to recognize newly-encountered peptide epitopes from 
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pathogens.  However, certain subsets of human T cells, such as invariant natural killer T (iNKT) cells, mucosal-
associated invariant T (MAIT) cells, and germline-encoded mycolyl-reactive (GEM) T cells reliably generate T 
cell receptors (TCRs) that are conserved among genetically diverse humans, and in some cases, across 
species (1).  Recent data indicate that T cells expressing such invariant TCRs comprise a significant fraction of 
all human T cells, estimated in the range of 10 to 20 percent (2).  Further, these conserved T cell subsets are 
not restricted by major histocompatibility (MHC)-encoded antigen presenting molecules, but instead can 
recognize different chemical classes of antigens presented by non-polymorphic antigen presenting molecules 
including CD1, MR1 or HLA-E (3).  One of these conserved T cell populations, iNKT cells, recognizes specific 
glycolipids presented by CD1d molecules.  Following activation, iNKT cells respond rapidly with vigorous 
cytokine production that can profoundly shape immune responses (4).   
  
Although a glycolipid antigen for iNKT cells was identified from a marine sponge more than 20 years ago as 
part of a chemical library screen (5), the origins and chemical identities of physiologically-relevant antigens that 
drive selection and activation of iNKT cells remain controversial.  Natural antigenic glycolipids have been 
detected from various foreign sources, including non-pathogenic -proteobacteria (6-8), spirochetes (9), and 
other microbes such as Streptococcus pneumoniae (10), and Bacteroides fragilis (11, 12).   These known 
microbial lipid antigens for iNKT cells share a key biochemical feature, namely an -anomeric linkage of one 
hexose sugar to the lipid backbone.  Mammals abundantly produce -linked hexosylceramides, 
glucosylceramide and galactosylceramide, but were not previously thought to produce -linked 
hexosylceramides.  Therefore, a major principle of antigen recognition by iNKT cells has been that self-
glycolipids are -linked and not strongly recognized, while pathogens produce lipids that are recognized as 
foreign based on their -anomeric linkage (5).  However, pathogen-derived lipids presumably do not explain 
the TCR- and CD1d-dependent activation of iNKT cells during positive selection in the thymus, or in settings 
such as viral infection, cancer, or sterile inflammation (4).  Endogenous lipids have long been proposed to 
activate iNKT cells in these settings.  
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It is possible that the longstanding view that mammalian monohexosylceramides are always -linked is 
incorrect.  Kain and colleagues showed that antibodies raised against -linked glycosphingolipids could stain 
mammalian tissues (13).  We recently fractionated mammalian milk-derived lipids, finding that antigenic 
substances were enriched in the hexosylceramide-containing fraction, and that antigenicity was not abrogated 
by -specific glycosidases or chromatographic depletion of -glucosylceramides (14, 15).  Both studies point to 
the possibility that -linked lipids are produced in mammalian tissues.  However, if they exist, they are likely 
scarce compounds and they have not been isolated in sufficient yield to confirm -anomeric structures through 
direct biochemical analysis.  Given the importance of the ‘-linked self-lipid hypothesis’ to iNKT cell biology, we 
sought to identify mammal-derived antigenic lipids. 
 
Here, we used soluble iNKT TCR and soluble CD1d to capture the subset of lipids from cow’s milk that form 
stable TCR-lipid-CD1d complex through direct analysis of TCR-lipid-CD1d complexes.  Combining this TCR 
‘trapping’ of CD1d-lipid antigen complexes with nanoelectrospray ionization (ESI) mass spectrometry (MS) and 
liquid chromatography-mass spectrometry (LC-MS), we could detect monohexosylceramides from cow’s milk 
as lipid antigens.  Using MS-based methods, we determined that the captured lipid antigens were -linked 
monohexosylceramides.  This study identifies the biochemical structures of natural cow’s milk-derived lipid 
antigens as-anomeric hexosylceramides, supporting the hypothesis that -linked lipids are iNKT cell 
antigens even in the absence of pathogens.  
 
 
 
Results 
 
Pre-purification of milk lipid antigens for iNKT cells.  We previously showed that the glucosylceramide-
containing fraction of cow’s milk contains antigenic lipids for iNKT cells (14, 15).  To further purify and identify 
the milk-derived lipid antigens, we digested a milk hexosylceramide lipid fraction with -glucosidase to destroy 
the -linked glucosylceramides.  Thin layer chromatography (TLC) showed that this treatment markedly 
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reduced the total mass of glycolipids co-migrating with a glucosylceramide standard, yet did not reduce the 
potency of iNKT cell activation (Fig. 1A).  This result could be explained if the starting material was 
predominantly composed of non-antigenic -linked glucosylceramides, and antigenic -linked 
hexosylceramides were present in milk that survived the enzyme treatment.  To address this possibility, we 
used a TLC separation method that resolved monohexosylceramide - and - anomers (15), yielding two 
bands.  Only the lower band, which co-migrated with an -glucosylceramide standard, stimulated an iNKT cell 
response (Fig. 1B), suggesting that -linked hexosylceramides could be present.  However, this interpretation 
is contrary to the prevailing view that mammalian products contain only -linked hexosylceramides.  The lower 
band that activated iNKT cells (Fig. 1A,B) which we refer to as the “activity-enriched” fraction, represented a 
very small fraction of total milk hexosylceramides, which provided an obstacle to formal biochemical 
identification of the antigen.  Thus, we considered new approaches to antigen discovery. 
 
Milk lipids mediate CD1d-TCR binding.  Nearly all prior approaches to antigen discovery, including that 
described above (Fig. 1A), have relied on a correlation between two assays that separately measure T cell 
activation and biochemical content.  The final antigen identification relies on the premise that the most readily 
detectable molecules are also the T cell stimulants.  By definition, antigenic lipids ligate TCRs to antigen-
presenting molecules with higher affinity than non-antigenic lipids, so we reasoned that a recombinant iNKT 
TCR with relatively high affinity for CD1d--galactosylceramide complexes, known as 2C12 (16), might 
selectively trap those CD1d complexes carrying milk-derived antigens, while leaving behind CD1d molecules 
that were bound to non-antigenic lipids.  Such a TCR trap approach was recently used to identify CD1a 
autoantigens (17).  We hypothesized that this approach might be feasible for CD1d and milk-derived antigens, 
since partially-enriched milk fractions could mediate the physical binding of CD1d tetramers to cells expressing 
an iNKT cell V14J18 V8.2J2.1 TCR, but not to cells expressing a sulfatide-reactive diverse NKT cell 
V1J26 V16J2.1 TCR (18, 19).  Staining of iNKT TCR-expressing cells with CD1d tetramers loaded with 
activity-enriched milk lipids was stronger than staining with unloaded CD1d tetramers, but weaker than 
tetramers generated with known potent lipid antigens -galactosylceramide and -glucosylceramide (Fig. 1C).  
Thus, cow’s milk contained compounds capable of mediating CD1d-TCR binding.  
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TCR Trap Assay.  To develop a cell-free assay to detect lipid antigens, we tested the TCR trap system by 
loading recombinant soluble CD1d with synthetic -glucosylceramide, and then mixing this antigen-loaded 
CD1d with recombinant soluble iNKT cell TCR monomers.  The subset of CD1d proteins carrying -
glucosylceramide was expected to bind TCR heterodimers leading to the formation of a higher molecular 
weight ternary complex, which could be purified by size exclusion gel chromatography.  A mixture of -
glucosylceramide-treated CD1d and TCRs showed a large early fraction that eluted prior to separate CD1d 
and TCR monomers (Fig. 2A), consistent with a larger protein complex.  After eluting lipids from this fraction 
using a mixture of chloroform and methanol, positive mode nanoelectrospray MS identified a prominent ion at 
m/z 832.7, corresponding to -glucosylceramide ([M+Na], M=C48H91NO8), as well as its isotopes.  The lack of 
other ions present above background levels indicated that lipids from culture media or those potentially carried 
by the outer surface of CD1d or TCRs did not substantially confound the analysis (Fig. 2B).  Thus, -
glucosylceramide performed its expected role in ligating CD1d to TCR, and direct analysis of CD1d-lipid-TCR 
complexes was sufficient to identify the ligating molecule without interference by other substances adherent to 
the lipid-protein complex.   
 
Next, to identify unknown lipids, we used this TCR trap assay with CD1d molecules that had been loaded with 
activity-enriched cow’s milk monohexosylceramides (Fig. 1A,B).  A small but detectable peak was observed in 
the early size exclusion fractions and this showed no overlap with CD1d or TCR monomer fractions (Fig. 2C).  
Coomassie staining of the early fraction revealed three proteins matching the apparent molecular weights of 
CD1d, 2m, and TCR with band similar intensity, consistent with 1:1:1 stoichiometry (Fig. 2D).  The peak 
height of the protein trace of the early eluting fraction made with milk lipids (Fig. 2C) was substantially lower 
than that of the early fraction made with CD1d carrying synthetic -glucosylceramide (Fig. 2A), suggesting that 
TCRs bound to a small fraction of the total pool of CD1d-lipid complexes present.  However, since this peak 
was observed at the same elution time as the synthetic -glucosylceramide standard-loaded CD1d, it 
suggested that the milk lipid-derived ternary complex carried a high-affinity antigen.   
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Nanoelectrospray analysis of all eluted milk lipids in the late fraction containing CD1d and TCR monomers 
found numerous ions, and the mass intervals among the most abundant ions were diverse, suggesting the 
presence of structurally diverse lipids from many classes (Fig. 3A, upper).  In contrast, the early fraction, which 
contained CD1d-TCR complexes, showed fewer eluted ions (Fig. 3A, lower).  The lower peak height from the 
size exclusion tracing and the less complex MS profiles suggested that the iNKT cell TCR selected small 
subset of CD1d-milk lipid complexes from among all CD1d-lipid complexes present in the starting material.  In 
fact, nearly all nanoelectrospray MS signals derived from the early-eluting CD1d-TCR complexes could be 
accounted for by a single alkane series comprised of lipids of m/z 710.7, apparent chain-length analogs (m/z 
724.7, 738.7, 752.6, 794.7, 808.8, 822.8, 836.8), and the isotopes of these lipids. 
 
TCR ligands identified using nanoelectrospray MS.  Next we identified the lipid ligands trapped-in or 
excluded-from CD1d-TCR complexes using shotgun nanoelectrospray with multi-stage ion trap MS.  This 
method provides high sensitivity, broad detection, and structural information from collision-induced dissociation 
(CID), but offers relatively low mass accuracy.  Considering the lipids eluted from the late fraction containing 
CD1d and TCR monomers, CID-MS of selected ions at m/z 738.4, 753.5, and 808.5 identified 
phosphatidylethanolamine, sphingomyelin, and phosphatidylcholine (Fig. 3B-D).  In addition, fragments from 
the ion at m/z 722.6 corresponded a hexosylceramide whose two fatty acid chains had a combined lipid tail 
length of C34 with one unsaturation (Fig. 3E).   This ‘type 1’ monohexosylceramide collision pattern was 
characterized by a dehydration (loss of 18 u, m/z 704.5), loss of a hexosyl unit (162 u, m/z 560.5), and loss of 
both fragments (loss of 180 u, m/z 542.4).  In contrast, ions from early fraction containing CD1d-TCR 
complexes did not show detectable signals for phosphatidylethanolamine, sphingomyelin, or 
phosphatidylcholine.  Instead, complexes in the early fraction released matched expected masses of a ‘type 2’ 
hexosylceramide, which unlike type 1 patterns, lacked a dehydration ion but did show a loss of 162 u.  In fact, 
the abundant ions in the early fraction were all accounted for by single alkane series corresponding to an 
monohexosylceramide with an overall lipid length ranging between C33 (m/z 710.7) and C42 (m/z 836.8).  
Separate analysis of six members of this alkane series demonstrated highly reproducible ‘type 2’ collision 
pattern (Fig. 3F).  
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The detailed profiles of these released lipids suggested several general conclusions.  First, monomeric CD1d 
proteins were bound to phospholipids, sphingomyelin, type 1 hexosylceramide, as well as other lipids that were 
not specifically identified (Fig. 3A).  Second, TCR-CD1d complex formation largely or completely excluded 
CD1d bound to phosphatidylcholine (m/z 808.6 with the m/z 749.3 product), sphingomyelin (m/z 753.6 with m/z 
694.4 product), phosphatidylethanolamine (m/z 738.5 with m/z 695.3 product), and the type 1 hexosylceramide 
with a monounsaturated lipid tail (m/z 722.6 with m/z 542.4 fragment).  Third, lipids eluted from the TCR-CD1d 
complexes contained type 2 monohexosylceramides ranging from C33-42 in chain length (Fig. 3A).  Further, 
the characteristic patterns of loss in CID analyses by type 1 (18, 162, and 180 u) and type 2 (162 u) 
hexosylceramides implicated a differing conformation of these ceramide-based lipids.  This interpretation is 
consistent with the TCR discriminating structural classes of lipids including glycoslyceramides, and possibly - 
versus -linked hexosylceramides.   
 
The molar concentrations of hexosylceramides eluted from the early and late complexes were determined 
using HPLC-MS in comparison to standards, and this material tested for the ability to elicit cytokine production 
from an iNKT cell hybridoma, DN32.  The late fraction did not have detectable activity, while the molar activity 
observed in the early fraction was similar to that of a synthetic antigen for iNKT cells known as -
galactosylceramide, KRN7000 (Fig. 3G).  Thus, our approach was successful as a TCR-based affinity trap for 
selecting antigenic glycolipids that ligate TCR to CD1d out of a complex mixture of natural lipids.  The 
equipotency of type 2 hexosylceramides and -galactosylceramide was consistent with the type 2 
hexosylceramides being an -linked lipid.  Although only trace amounts of the type 2 monohexosylceramide 
could be recovered from ternary complexes of CD1d-lipid-TCR, 1D-proton nuclear magnetic resonance 
spectroscopy (NMR) carried out on a 900 MHz instrument identified a doublet with a chemical shit of 4.85 ppm, 
consistent with the anomeric proton resonance of -monohexosylceramide (Fig. S1) (15). 
 
Identification of ligands at high mass resolution.  To further biochemically characterize the lipids that 
promoted the formation of TCR-lipid-CD1d complexes, we separately analyzed eluents from milk lipid-treated 
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protein monomers present in the late fraction, untreated CD1d, and untreated TCR (Fig. 4).  Here, we took 
advantage of the higher mass accuracy of a quadrupole time-of-flight (Q-ToF) mass detector coupled with 
chromatographic separation in normal-phase HPLC-MS to confirm the identity of the key ions.  Using this 
method, the major ions previously identified by nanoelectrospray MS were confirmed and assigned based on 
high mass accuracy and HPLC retention time, compared with standards as phosphatidylcholine (38.1 min, m/z 
786.601), phosphatidylethanolamine (20.5 min, m/z 716.523), type 1 hexosylceramide (4.1 min, m/z 700.578), 
and type 2 hexosylceramide (4.1 min, m/z 702.590, 716.604 and 786.682) (Figure 4).  No substantial false 
positive signals were derived from lipids released from the TCR, indicating that the lipids detected were carried 
by CD1d.  As seen with the nanospray method (Fig. 3), CD1d alone and mixed CD1d and TCR monomers 
bound phosphatidylcholine, phosphatidylethanolamine, and type 1 monohexosylceramides (Fig. 4 and S2), but 
these were excluded from CD1d-TCR complexes.  Conversely, type 2 hexosylceramides eluted with low or 
undetectable signals from milk lipid treated monomers, but were highly enriched in CD1d-TCR complexes.  
Thus, CD1d bound many lipids, but the iNKT TCRs selectively captured CD1d bound to type 2 
hexosylceramides (Fig. S3).   
 
Structural identification of type 1 and 2 hexosylceramides.  Despite their strikingly-different patterns of 
binding within, or being excluded from, CD1d-TCR complexes, normal-phase HPLC-MS showed that type 1 
and 2 hexosylceramides had equivalent retention time and the same underlying molecular composition, except 
for variations in lipid tail length and unsaturation.  CID-MS experiments using the ion trap architecture, however 
showed different fragmentation patterns for type 1 and type 2 hexosylceramides (Fig. 3).  We next asked 
whether anomeric variants could be distinguished by CID-MS.  First, we produced synthetic standards differing 
only in the stereochemistry of their hexose attachment.  Both glucosyl and galactosyl variants were 
synthesized, with dihydrosphingosine (d18:0) as their lipid backbones based on the molecular composition of 
type 2 hexosylceramides identified in the milk-derived early fraction.  These synthetic standards had a similar 
retention time by normal-phase HPLC to the early-eluting milk lipids (Fig. S4).  The synthetic standards were 
tested for their ability to activate the DN32 iNKT cell hybridoma after loading in CD1d-expressing RAW264.7 
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cells.  For both glucosyl and galactosyl synthetic standards, activity was observed for the -linked variants, but 
not for the -linked variants (Fig. 5A).   
 
Positive mode ion trap CID-MS of sodiated adducts of these synthetic hexosylceramides was carried out under 
conditions that matched those used for milk-derived compounds (Fig. 3), and over a range of collision energy 
settings (Fig. 5B).  Collision of the -glucosylceramide synthetic standard demonstrated almost exclusively a 
primary loss of 162 u, matching the pattern for type 2 milk-derived hexosylceramides.  In contrast, -glucosyl 
standards matched the fragmentation pattern seen for type 1 hexosylceramides from milk, showing a loss of 18 
u at a similar frequency as loss of 162 u.  Although both patterns involved the loss of 162 u as a hexosyl unit, 
analysis over a range of collision energy demonstrated that -glucosylceramide also lost 18 u and 180 u, 
whereas -glucosylceramide showed neither of these fragmentations at a substantial frequency.  Parallel 
analyses of - and -galactosylceramide standards showed similar characteristic - and - collision patterns 
(Fig. S5).  Matched synthetic - and -glucosylceramide and galactosylceramide standards based on the type 
1 hexosylceramide lipid backbone structure showed similar characteristic - and - collision patterns, 
demonstrating that the anomeric linkage discrimination by this technique was not limited to 
dihydrosphingosine-based glycosphingolipids (Fig. S6).  Ion trap CID-MS of -galactosylceramide with a 
phytosphingosine base also fragmented with the pattern matching type 2 hexosylceramides.  We concluded 
from these experiments that linear ion trap MS could sensitively distinguish - from -hexosylceramides under 
the conditions measured for a range of lipids with differing tail lengths and unsaturations. 
 
We compared the collision patterns of the major hexosylceramide ions from cow’s milk lipids.  Unfractionated 
cow’s milk glucosylceramides demonstrated a fragmentation pattern characteristic of -hexosylceramide 
standards (Fig. 5C), consistent with the main lipid in the starting material being -glucosylceramide.  The 
activity-enriched cow’s milk glucosylceramide showed a -hexosylceramide collision pattern, but with an 
increased frequency of a type 2 pattern characterized by the loss of the sugar headgroup (162 u).  The 
antigenic lipids captured in the TCR trap assay showed the fragmentation pattern typical of -
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hexosylceramides.  We concluded from these experiments that the TCR trap captured type 2 -linked 
hexosylceramides from cow’s milk.  To address the possibility that these type 2 hexosylceramides were 
derived from microbes present in cow’s milk, we purified the monohexosylceramide fraction from calf thymus, a 
mammalian lipid source previously shown activate iNKT cells (15).  Several ions with the m/z seen in cow’s 
milk were also present in calf thymus, including ions corresponding to type 2 hexosylceramides m/z 724.7 and 
808.8 (Fig. S7).  Linear ion trap CID-MS of untreated calf thymus hexosylceramides showed a characteristic -
hexosylceramide pattern.  After activity enrichment of thymus hexosylceramides by treatment with -
glucosidase and TLC fractionation as in Fig. 1, we observed a collision pattern consistent with the presence of 
-hexosylceramides, based on a substantial increase in the abundance of the ion representing a primary loss 
of the sugar headgroup. 
 
Discussion  
Uncovering the specific antigens recognized by iNKT cells is central to understanding their roles in health and 
disease.  Although lipid antigens for iNKT cells have been identified in the microbial world (6-10), experimental 
evidence has demonstrated important roles for endogenous and environmental lipid antigens.  Several 
candidate endogenous lipid antigens have been proposed (13, 14, 20-22), though technical limitations in the 
ability to detect these antigens has hampered our ability to determine their contextual roles.  Here, we provide 
direct biochemical evidence for -hexosylceramide derived from a mammalian source, cow’s milk.   
 
There is increasing evidence that iNKT cells encounter lipid antigens at mucosal surfaces.  CD1-dependent 
immunomodulatory lipids have been identified in gut microbes (11, 12), pollen (23), house dust (24), and in our 
work, cow’s milk.  We have previously demonstrated that cow’s milk contains substantially more lipid antigen 
activity than human or mouse milk.  Although native triglycerides are removed from infant formula during 
processing, bovine polar lipids, including lipid antigens for iNKT cells, are retained in the final product (15).  
Studies in germ-free mice suggest that the iNKT cell compartment can be shaped by CD1d-lipid signals in the 
enteral tract (11, 25), and thus early-life exposure to cow’s milk-based infant formula might similarly shape 
human mucosal iNKT cells in early life.  In adult mice, orally-delivered antigen activates iNKT cells in the gut 
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(26), suggesting that exposure to dietary lipid antigens in adult life may also have consequences.  Interestingly, 
it is unclear whether cows have iNKT cells (27), as their CD1d does not present the long-chain -
galactosylceramide commonly used as a tool in mice and humans (28).  Bovine CD1d can present short-chain 
-galactosylceramides (28, 29), and it is possible that an increased presence of -hexosylceramdies in cow’s 
milk and tissues could lead to thymic deletion of iNKT cells, as has been observed in mice in the presence of 
exogenous -galactosylceramide (30). 
 
Although the bulk solids in milk derive overwhelmingly from mammary glands, we cannot formally rule out that 
colonizing microbes synthesized, or played a role in the synthesis of the -hexosylceramides present in cow’s 
milk.  Several features of our data argue against possible contamination of milk by microbial products.  We 
have previously observed iNKT cell-stimulating activity in the monohexosylceramide fractions of the milks, sera, 
and internal organs of multiple animal species (14, 15).  The N-acyl chain usage of the -hexosylceramides 
that we identified in this report mirror that of the bulk -glucosylceramides in cow’s milk, suggesting that these 
lipids are of mammalian origin.  We also identified type 2 hexosylceramides from calf thymus with the same 
m/z as those in cow’s milk.  These thymic hexosylceramides, like those found in cow’s milk, shifted from a -
hexosylceramide pattern toward a characteristic -hexosylceramide collision pattern after activity enrichment. 
Currently, the level of -hexosylceramide identified from cow’s milk, a relatively abundant and potent natural 
source of lipid antigen, is near the limit of detection for the TCR trap assay system.  However, we are 
continuing to improve the system so that lipids can be captured and identified from smaller amounts of source 
material. 
 
The stereochemistry of organic molecules can have significant biological consequences.  Determination of 
stereochemistry has largely been accomplished by NMR.  However, for rare compounds such as endogenous 
iNKT cell lipid antigens, purification of sufficient material for complete, multi-dimensional NMR analysis is 
currently not possible.  As shown in this report and others (31, 32), CID-MS can also be used to determine 
stereochemical features.  We tested - and -linked synthetic standards with both sphingosine and 
dihydrosphingosine bases, and found consistent characteristic - and - fragmentation patterns, showing that 
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this detection method was not limited to certain lipid backbones.  Interestingly, these collision patterns were 
only observed with selected positive mode adducts, including sodium and rubidium.  We hypothesize that for 
the -hexosylceramide structure, positive adducts with a sufficiently large valence, such as sodium and 
rubidium, can coordinate elements on both sides of the glycoside bond, stabilizing the glycoside bond during 
collision, thus reducing the propensity for cleavage of the sugar headgroup.  For -hexosylceramide, this 
headgroup stabilization may be sterically hindered, thus allowing for fragmentation across the glycoside bond 
at a lower energy.   
 
Identification of CD1d-presented lipid antigens has largely relied on indirect evidence such as extrapolation 
from cells deficient in lipid synthesis genes (22, 33), or fractionation of crude lipid sources with activity tracking 
within these fractions (14, 20).  These approaches have been useful, but do not directly demonstrate 
recognition by the TCR, and rely on correlations between two or more assays.  Here, we used a direct method 
for antigen discovery, the TCR trap assay.  This approach uses ternary complex formation both as the 
preparative method to recover lipids of interest and as the assay demonstrating the lipid’s role in ligating CD1d 
and TCR.  The TCR trap assay has also been used successfully to identify CD1a ligands (17), and could be 
used to identify ligands for other CD1 isoforms, or even MR1.  This approach will allow tracking of rare lipids 
from virtually any source, including from complex mixtures, or limited starting materials, which represent 
common challenges when starting with mammalian tissues and cells.  
 
Methods and materials 
Initial lipid activity enrichment was performed as previously described (15).  Mass spectrometry analyses were 
performed on a Thermo-Fisher LXQ ion trap mass spectrometer or an Agilent 6520 Accurate-Mass Q-ToF with 
HPLC.  For details of experimental conditions and analysis, see SI Materials and Methods. 
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Figure legends 
 
Fig.1. iNKT cell activation by milk hexosylceramides.  (A)  A cow’s milk glucosylceramide-fraction was digested 
with recombinant lysosomal glucosidase to reduce -glucosylceramide.  The remaining material detected at 
the monohexosylceramide retention time was purified by preparative TLC and further resolved to upper and 
lower fractions.  (B) TLC fractions were tested for activity by co-culture with the DN32 iNKT cell hybridoma and 
CD1d-transfected RAW-264.7 cells.  (C) CD1d monomers loaded with the indicated lipids were assembled into 
tetramers that were used to stain BW58 cells transfected with an iNKT cell TCR or with a diverse NKT cell TCR 
that does not recognize -galactosylceramide.  Numbers indicate geometric mean fluorescence values.  Data 
are representative of two independent experiments performed with separate starting material.   
 
Fig. 2. TCR trap assay.  (A) Synthetic -glucosylceramide was loaded in recombinant CD1d molecules, mixed 
with recombinant iNKT cell TCRs (2C12), and run over a size-exclusion chromatography column.  (B) Lipids 
were eluted from the early fraction excluded from the column and analyzed by linear ion trap MS.  A dominant 
ion corresponding to the -glucosylceramide standard was recovered and few other ions were detected.  (C) 
The activity-enriched milk monohexosylceramide fraction was loaded in CD1d and treated as in (Fig. 2A).  (D) 
The early fraction, CD1d alone, or TCR alone, were resolved on an SDS-PAGE gel and total proteins stained, 
yielding bands corresponding to TCR, CD1d, and 2M.  Data are representative of two independent 
experiments performed with separate starting material.   
 
Fig. 3. Linear ion trap MS analysis of CD1-lipid-TCR complexes.  (A) Lipids extracted from the TCR trap assay 
fractions indicated Fig. 2C were analyzed by linear ion trap MS.  Prominent ions from the late fraction were 
identified as (B) phosphatidylcholine, (C) sphingomyelin, (D) phosphatidylethanolamine, and (E) type 1 
monohexosylceramide.  (F) All major ions in the early fraction were an alkane series, and collision of 6 of the 
most abundant ions generated type 2 monohexosylceramide patterns.  (G) Lipids were extracted from the early 
fraction, quantified, and co-cultured with the DN32 iNKT cell hybridoma and CD1d-transfected RAW-264.7 
cells.  Experiments were performed on lipids extracted two independent TCR trap assays.   
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Fig. 4. HPLC-MS analysis with Q-Tof MS detection.  Lipids extracted from TCR trap assay fractions were 
analyzed by Q-ToF HPLC-MS experiments to provide high mass accuracy confirmation of the structures 
deduced in Fig. 3, measure lipid binding to TCR and to measure retention time in comparison with standards.  
HPLC tracings are shown for selected targeted ions based on predicted masses for the structures identified in 
Fig. 3.  Experiments were performed on lipids extracted two independent TCR trap assays.   
 
Fig. 5. Linear ion trap MS distinguishes - from -hexosylceramides.  (A) Lipid standards were synthesized 
based on the structures of the type 2 monohexosylceramides and tested in co-culture with the DN32 iNKT cell 
hybridoma and CD1d-transfected RAW-264.7 cells.  (B) MS-MS of sodiated adducts demonstrated 
characteristic fragmentation patterns for - and -glucosylceramide synthetic standards when studied over a 
range of collision energy settings.  (C) Linear ion trap MS-MS was performed on the cow’s milk unenriched, 
activity-enriched, and TCR trap early fraction lipids.  Three experiments were performed for (A) and (B).  
Experiments in (C) were performed on lipids extracted two independent TCR trap assays. 
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Supporting Information    
 
Supplementary figure legends 
 
Fig. S1. One-dimensional proton NMR.  Lipids eluted from the TCR trap early fraction were analyzed by one-
dimensional proton NMR.  A resonance with a chemical shift of 4.85 ppm was observed, characteristic of -
monohexosylceramide.  This analysis was performed on one of two independent early fraction lipid eluates.  
 
Fig. S2. HPLC-Q-ToF-MS collision spectra for type 1 and type 2 hexosylceramides.  TCR trap assay (A) late 
fraction type 1 monohexosylceramides and (B) early fraction type 2 monohexosylceramides were analyzed by 
HPLC coupled to Q-ToF MS shown as extracted ion chromatograms (left) and CID-MS (right).  Experiments 
were performed on lipids extracted two independent TCR trap assays and representative HPLC tracings are 
shown.   
 
Fig. S3. Type 1 and 2 hexosylceramide ions determined by Q-tof MS.  TCR trap assay late fraction type 1 (top 
panel) monohexosylceramides and early fraction type 2 (bottom panel) monohexosylceramides were analyzed 
by high mass accuracy Q-ToF MS.  HPLC elution times of 3.4-5 min are shown, corresponding to the elution 
time of monohexosylceramide standards.  Experiments were performed on lipids extracted two independent 
TCR trap assays, and representative HPLC tracings are shown.   
 
Fig. S4. TCR trap early fraction co-elutes with a panel of synthetic monohexosylceramides.  HPLC-Q-ToF-MS 
tracings of the synthetic monohexosylceramide standards with [M+H]+, m/z 786.682 (Fig. 5A) and TCR trap 
assay early fraction are shown.  Experiments with synthetic lipid standards were performed at least three times.  
Experiments were performed on lipids extracted two independent TCR trap assays and representative HPLC 
tracings are shown.   
 
Fig. S5. Linear ion trap MS distinguishes - from -galactosylceramides.  As in Fig. 5B, - and - 
galactosylceramide synthetic standards were performed over a range of collision energies.  Chemical 
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structures of - and -galactosylceramide with deduced fragmentations are shown.  MS-MS of sodiated 
adducts demonstrated characteristic fragmentation patterns, like those observed for - glucosylceramide and 
-glucosylceramide synthetic standards.  Three independent experiments were performed.     
 
Fig. S6. Linear ion trap MS distinguishes - from -glycosylceramides with a sphingosine base.  Using linear 
ion trap CID-MS, the synthetic standards with a d18:1 sphingosine base (structures shown) were analyzed.  
MS-MS tracings are shown.  Three independent experiments were performed.     
 
Fig. S7. Monohexosylceramides from calf thymus.  (A) The monohexosylceramide fraction from calf thymus 
was purified by normal-phase TLC and analyzed by linear ion trap MS.  Monohexosylceramides were detected 
in the thymus with the same m/z as those identified in cow’s milk, including the type 2 monohexosylceramides 
m/z 724.7 and 808.8.  (B) Calf thymus hexosylceramides were subjected to activity enrichment as in Fig. 1A,B.  
Collision of the m/z 724.7 and 808.8 before (top panels) and after activity enrichment (bottom panels) 
demonstrated an increase in loss of 162 u following activity enrichment, as observed for cow’s milk (Fig. 5C).  
MS experiments were performed twice.  
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SI Methods and materials 
 
Lipids 
Starting with 50 mg of cow’s milk glucocerebrosides (Matreya), two independent  experiments were done to 
enrich the lipids in the starting material that activated iNKT cells (referred to as the “activity-enriched” fraction) 
(15).  Briefly, lipids were first digested with recombinant human lysosomal glucocerebrosidase (Velaglucerase 
Alfa, Shire).  The monohexosylceramides remaining after digestion were recovered by preparative TLC.  The 
active lipid fraction was further isolated using the HICMW system (15).  Lipids were resolved with normal 
phase TLC and visualized by staining with an -napthol sulfuric acid (Sigma) solution and charring.  Calf 
thymus (Research 87) monohexosylceramides were purified as previously described (15) and activity 
enrichment was carried out as for cow’s milk lipids.  -glucosylceramide (d18:1/24:1) was purchased from 
Avanti polar lipids.   Synthetic lipids, including -galactosylceramide KRN7000 (d18:0-C26:0, containing a 
phytosphingosine base with a 26 carbon unsaturated N-acyl chain) were synthesized, -glucosylceramide 
(d18:0-C22:0, containing a dihydrosphingosine base),  -glucosylceramide (d18:0-C22:0, containing a 
dihydrosphingosine base), -galactosylceramide (d18:0-C22:0, containing a dihydrosphingosine base), and -
galactosylceramide (d18:0-C22:0, containing a dihydrosphingosine base), were synthesized as previously 
described (34). 
 
CD1d tetramer staining of invariant and Type-2 NKT cell lines 
Invariant NKT (V14J18 V8.2J2.1, CDR3 DRGSALGRLHFGAG, CDR3 GDAGGNYAEQFFGPG) and 
diverse NKT (V1J26 V16J2.1, CDR3SEQNNYAQGLTFGLG, CDR3 SFWGAYAEQFFGPG) BW58 cell 
lines were generated using retroviral transduction (35). Recombinant mouse CD1d tetramers (36) were loaded 
with lipids dissolved in 0.5% Tyloxapol (Sigma) with Tris buffered saline pH 8.0 at a 3:1 lipid: protein molar ratio. 
Cell lines with invariant and diverse NKT cell TCRs co-stained with TCR (clone H57-597) and CD1d tetramers 
loaded with C24:1 -galactosylceramide (PBS44) (kindly provided by Paul Savage, Brigham Young University), 
- glucosylceramide, activity enriched milk antigen or unloaded CD1d tetramer. 
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TCR trap assay 
Recombinant V14J18 V8.2J2.5 TCR (2C12) TCR, CDR3 GDEGYTQYFGPG was prepared as 
previously described for the production of recombinant V14J18 V7 TCR (37). Following lipid loading, 
excess Tyloxapol was removed from recombinant mouse CD1d using ion exchange chromatography (Mono Q 
10/100GL, GE Healthcare).  Mouse CD1d and soluble 2C12 TCR were passaged separately over a Superdex-
200 16/60 gel-filtration column (GE healthcare), just prior to the generation of ternary complexes, to remove 
any protein aggregates.  CD1d-milk Ag-TCR and CD1d--glucosylceramide-TCR ternary complexes were 
generated by mixing equal amounts of CD1d and by passage over Superdex-200 column at a flow rate of 
0.5mls/min.  Gel filtration fractions were analyzed on a 12% SDS-PAGE gels (Biorad) using Coomassie blue 
stain.  
 
iNKT cell activation assay 
Lipid activity assays were performed with the DN32 iNKT cell hybridoma (38) and CD1d-transfected RAW-
264.7 cells (39).  Briefly, lipids were dried under a nitrogen stream, then sonicated in serum-containing assay 
media.  5 x104 DN32 cells and 5 x104 CD1d-transfected RAW-264.7 cells were co-cultured with lipids for 16 hr 
at 37 ºC.  Assays were performed in RPMI-1640 media supplemented with 10% fetal calf serum (Gemini Bio), 
penicillin/streptomycin, L-glutamine and -mercaptoethanol (Life Technologies) at 37ºC in 5% CO2.  For X-Y 
graphs, standard error of the mean is shown. 
 
Nanospray ESI-MS  
All organic solvents were HPLC grade.  Lipids were extracted from CD1d proteins were with chloroform, 
methanol and water according to the method of Bligh and Dyer (40).  Briefly, protein samples in 200 µl 10mM 
Tris pH 8.0 150 mM NaCl were transferred to 15 ml glass tubes, treated with 0.75 ml of chloroform:methanol 
(1:2 (v:v)), vortexed for 1 min to denature the protein and extract lipids.  The mixture was treated with 0.25 ml 
of chloroform and vortexed for 30 seconds, and then treated with 0.25 ml of water and vortexed for another 30 
seconds.  The mixture was centrifuged at 850 x g for 10 min to separate the layers.  The upper aqueous layer 
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was removed, and the lower organic lipid containing layer was transferred to another clean glass tube.  The 
organic solvents were dried under a liquid nitrogen stream and the lipid residue was re-dissolved in 
chloroform/methanol (1:2) and stored at -20 C.   For a shotgun lipid analysis, the extracted lipids were loaded 
onto a nanospray tip for electrospray mass spectrometry (ESI-MS) and multistage collision-induced 
dissociation tandem mass (CID-MS) using linear ion-trap mass spectrometer (LXQ, Thermo Scientific). 
Collision energy was 20–30% of maximum and product ions were trapped with a q value of 0.25.   
 
HPLC-MS analysis 
To obtain the accurate mass and retention time information, the extracted lipids from 25 – 400 g of CD1d 
protein and normalized to 25 µM based on the concentrations of input protein.  The normalized samples (25 µl) 
were dried and re-dissolved in 25 µl of starting mobile phase B (see below), and 20 µl were injected for HPLC-
ESI-MS analysis (Agilent 6520 Accurate-Mass Q-TOF and 1200 series HPLC system using a normal phase 
Varian MonoChrom Diol column, 3 µm x 150 mm x 2 mm, and running at 0.15 ml/min) according to the 
published methods (41).  The solvent mobile phases were (A) isopropanol/methanol (70:30, (v:v)) and (B) 
hexane/isopropanol (70:30, (v:v)).  Both mobile phases were supplemented with 0.1% formic acid and 0.05% 
ammonium hydroxide.  The gradient system was following: 0-10 min, 100% B; 10-17 min, 100% to 50% B; 17-
22 min, 50% B; 22-30 min, 50% to 0% B; 30-35 min 0% B; 35-40 min, 0% to 100% B; 40-44 min, 100% B; 
followed by additional 6 min 100% B post-run.  The glycolipid concentrations in the extracted fractions were 
estimated by comparing the peak areas of the extracted ion chromatograms to those of the external standard 
curves (-glucosylceramide d18:1/24:1).  All monohexosylceramide variants were assumed to have similar 
response factor for ionization.  For the synthetic glucosyl- or galactosylceramides, the normal phase HPLC 
elution system was optimized for resolution of individual compounds using an isocratic condition with mobile 
phase solvents of hexane/isopropyl alcohol (70:30 (v:v)), containing formic acid 0.1% (v:v) and ammonium 
hydroxide 0.05% (v:v).  The run was set at 0.15 ml/min for 10 min.  The synthetic compounds were eluted from 
4 to 6 min.  CID-MS experiments were performed with collision energy of 30 V and 1.3 m/z isolation width.   
 
NMR analysis 
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NMR was performed at the University of Georgia Complex Carbohydrate Research Center as previously 
described (15).  Samples were dissolved in 2:1 CDCl3-CD3OD followed by one-dimensional proton NMR 
acquired on a Varian VNMRS 900 MHz spectrometer at 27ºC.  
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